The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug ... Datroway, also called datopotamab deruxtecan, or Dato-DXd, was approved in Japan for a form ...

Beyond breast cancer, the potential for Dato-DXd in lung cancer ... Begin your TipRanks Premium journey today. Daiichi Sankyo Company (DSKYF) Company Description: Daiichi Sankyo Co., Ltd. engages ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

for datopotamab deruxtecan (Dato-DXd), an ADC targeting EGFR-mutated non–small cell lung cancer (NSCLC) developed by Daiichi Sankyo and AstraZeneca.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK ... Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the US for the treatment of adult ...

Narrow-moat Daiichi Sankyo’s third-quarter earnings were in line with our expectations. Despite its change in development strategy for recently approved Datroway (formerly known as Dato-DXd), we ...

Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...